Alzheimer's Disease Clinical Trials:
Navigating Diagnosis, Endpoints, and Challenges

INGENŪ CRO

Introduction

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory impairment, and behavioral changes.

The history of Alzheimer's disease can be traced back to 1906 when Dr. Alois Alzheimer, a German psychiatrist and neurologist, first identified and described the condition in a patient named Auguste Deter. Dr. Alzheimer observed her severe memory loss, cognitive decline, and behavioral changes, and upon her death, he performed an autopsy, discovering the presence of amyloid plaques and neurofibrillary tangles in her brain. These findings laid the foundation for our understanding of the disease.

Over the subsequent decades, research into Alzheimer's disease has evolved significantly. Initially, AD was considered a rare condition, but by the mid-20th century, it became recognized as the most common cause of dementia. Advances in molecular biology and genetics in the late 20th and early 21st centuries have furthered our understanding of the disease, particularly with the identification of genetic mutations associated with familial forms of AD, such as those in the amyloid precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2) genes.

In recent years, the focus of AD research has shifted towards early diagnosis and intervention, with the development of biomarkers, such as amyloid PET imaging and cerebrospinal fluid (CSF) analysis for Aβ and tau proteins, allowing for the detection of AD pathology even before clinical symptoms manifest. This shift has led to the identification of preclinical and prodromal stages of the disease, providing new opportunities for therapeutic intervention

iNGENŪ CRO

Book a Discovery Call to learn how iNGENū can deliver high-quality, cost-efficient, FDA-compliant research for your next clinical trial

Why Choose iNGENū CRO?

iNGENū is the FDA-centric Australian CRO championing disruptive, innovative biotech firms. We are physician-led, providing access to the full spectrum of clinical and non-clinical research services.

Local Trials, Global Approvals

Australian expertise combined with direct FDA submission capabilities, offering a streamlined path for global approval.

Disciplined, Cost-Efficient Execution

Every dollar is strategically allocated, eliminating unnecessary costs while maintaining the highest quality.

Australian Headquartered, Asia-Pacific Reach

Access high-quality trials in the Asia-Pacific region, enhancing speed and scalability.

Expertise From the Start

Engage directly with our team of highly qualified doctors and PhD scientists from the outset.

Ready to discuss your Clinical Trial?
For further information on how iNGENū can assist you to conduct your clinical trial, book a Discovery Call with one of our Advisors.

Key Characteristics

Characteristics of Alzheimer's Disease

1. **Pathophysiology:**
   - The hallmark features of Alzheimer's disease include the accumulation of amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau protein in the brain. These changes are believed to disrupt neuronal communication, cause synaptic dysfunction, and lead to neuronal death. The disease primarily affects the hippocampus and brain regions responsible for memory and cognitive function but spreads to other areas, causing widespread brain atrophy as it progresses.
2. **Clinical Presentation:**
   - Alzheimer's disease typically begins with subtle cognitive impairment, particularly in short-term memory. Early symptoms may include forgetting recent events, repeating questions, and misplacing items. As the disease progresses, cognitive decline becomes more pronounced, affecting language, problem-solving abilities, and visuospatial skills. In the moderate to severe stages, patients often experience disorientation, confusion, difficulty in performing familiar tasks, changes in mood and behavior, and eventually, a loss of ability to function independently. In the most advanced stages, patients become entirely dependent on others for care and may lose the ability to communicate effectively.

Stages of Alzheimer's Disease

Alzheimer's disease is generally categorized into three stages:

1. **Mild (Early Stage):**
   - Individuals may still function independently but experience memory lapses and difficulties in planning or solving problems. Early intervention at this stage can be critical in slowing disease progression.
2. **Moderate (Middle Stage):**
   - Symptoms become more noticeable and interfere with daily life; patients may forget personal history, become moody or withdrawn, and have difficulty with complex tasks. This stage often requires increased support from caregivers.
3. **Severe (Late Stage):**
   - Patients require round-the-clock care and assistance with daily activities, as they lose awareness of their surroundings and may have difficulty swallowing or controlling their movements.

Prevalence and Future Trends

Prevalence

- In the United States, the prevalence of Alzheimer's disease is projected to nearly double by 2050, reaching nearly 13 million individuals if current trends continue. This increase is primarily driven by the aging population, particularly the baby boomer generation, which is entering the age of highest risk for AD.
- The incidence of Alzheimer's disease, or the rate of new cases, is also expected to rise as the population ages. However, there is some evidence that the age-specific incidence of dementia, including Alzheimer's disease, may be declining in some high-income countries, possibly due to improved education, better management of cardiovascular risk factors, and healthier lifestyles.

Trend Analysis (2013-2023)

- Over the past decade, the prevalence of Alzheimer's disease has shown a consistent upward trend. This increase is largely driven by demographic changes, particularly the aging of the baby boomer generation, and improvements in diagnostic practices that have led to earlier detection and diagnosis of the disease. Increased awareness and understanding of the disease have also contributed to the rising number of diagnosed cases

Future Projections

If current trends continue, the prevalence of Alzheimer's disease is expected to nearly double by 2050, reaching close to 13 million individuals in the United States alone. This projection underscores the urgent need for effective preventive strategies, early diagnostic tools, and new therapeutic approaches to manage and mitigate the impact of the disease.

Market Overview

The market for Alzheimer's disease treatments is both significant and dynamic, driven by the high unmet medical need and the economic burden associated with the disease. In 2023, the global Alzheimer's disease therapeutics market was valued at approximately USD 5.6 billion. This market includes a range of pharmacological treatments aimed at managing the symptoms of the disease, as well as newer therapies targeting its underlying pathophysiology.

Future Projections for the Alzheimer's Disease Treatment Market

Growth Drivers

1. Increasing Prevalence

- The rising number of Alzheimer's disease cases, particularly among the aging population, is a primary driver of market growth.

2. Advancements in Therapeutic Development

- Ongoing research and development efforts are leading to the introduction of new therapeutic options, including disease-modifying therapies that target amyloid-beta and tau proteins, as well as emerging approaches such as gene therapy and immunotherapy.

3. Economic Burden

- The economic impact of Alzheimer's disease, including direct medical costs and indirect costs related to caregiving and lost productivity, is substantial. This economic burden has spurred investment in research and development, with the goal of reducing the overall cost of care through effective treatments.

Future Market Trends

- The Alzheimer's disease therapeutics market is expected to grow in the coming years, driven by several factors. The increasing prevalence of the disease, coupled with advancements in therapeutic development, is expected to lead to the introduction of new and more effective treatments.
- Furthermore, the market is witnessing increased investment from both pharmaceutical companies and VC firms, which is expected to accelerate the development of innovative treatment options. As the understanding of Alzheimer's disease continues to evolve, the market is anticipated to expand, offering new opportunities for companies and providing hope for patients and their families.

Key Drugs with Highest Earning Potential in the US

Drug Name	Company	Annual Revenue (USD)
Aricept (Donepezil)	Eisai/Pfizer	$800 million
Namenda (Memantine)	Allergan (AbbVie)	$700 million
Namzaric (Combination drug: Donepezil & Memantine)	Allergan (AbbVie)	Several hundred million
Lecanemab (Leqembi)	Eisai/Biogen	Projected over $1 billion
Donanemab (Kisunla)	Eli Lilly	Projected over $1 billion

Diagnostic Codes and Criteria

ICD-11 Code: 8A20.0

Diagnostic criteria according to ICD-11:

1. **Cognitive Impairment:**

- Diagnosis requires evidence of significant cognitive decline in one or more cognitive domains, such as memory, learning, language, executive function, and perceptual-motor abilities. This decline must represent a change from a previous level of functioning and interfere with the individual's independence in daily activities.

2. **Functional Decline:**

- The cognitive deficits must be severe enough to interfere with independence in daily life activities, such as managing finances, taking medications, or driving.

3. **Exclusion of Other Causes:**

- The diagnosis also requires the exclusion of other possible causes of cognitive impairment, such as other neurodegenerative conditions, cerebrovascular disease, or psychiatric disorders.

4. **Supportive Biomarker Evidence:**

- While biomarkers like amyloid PET imaging and cerebrospinal fluid analysis are not required by ICD-11, they can support the diagnosis in uncertain cases. Biomarkers such as amyloid PET imaging, cerebrospinal fluid analysis for amyloid-beta and tau proteins, and structural MRI can provide supportive evidence for pathology.

DSM-5 Diagnostic Criteria

- The DSM-5 criteria for Major Neurocognitive Disorder Due to Possible Alzheimer's Disease align closely with the ICD-11, focusing on significant cognitive decline in one or more domains, which interferes with daily functioning. The DSM-5 also categorizes the severity of the disorder into mild, moderate, and severe based on the extent of cognitive decline and the level of assistance required in daily activities.

Impact on Clinical & Research Perspectives

- The inclusion of biomarkers and recognition of early stages in the diagnostic criteria has had profound implications for clinical practice and research. Clinically, these criteria allow for more accurate and timely diagnoses, enabling healthcare providers to initiate treatment earlier in the disease course, which can be crucial in managing symptoms and slowing disease progression.
- From a research perspective, the updated criteria have led to more targeted and stratified clinical trials. Researchers can now focus on specific stages of the disease, such as the preclinical or prodromal stages, which has opened new avenues for exploring disease-modifying therapies. The use of biomarkers as endpoints in clinical trials has also provided more objective measures of treatment efficacy, complementing traditional cognitive and functional assessments.

Epidemiology

1. Age

- Age is the most significant risk factor for Alzheimer's disease. The prevalence of AD increases exponentially with age, particularly after the age of 65. Approximately 10% of individuals aged 65 and older are affected by AD, with the prevalence rising to nearly one-third among those aged 85 and older. This trend is largely attributed to age-related changes in the brain, such as amyloid-beta plaque buildup and tau protein tangles, which contribute to the development of the disease.

2. Gender

- Alzheimer's disease affects women more than men, with nearly two-thirds of AD patients being female. This disparity is partly due to the fact that women generally live longer than men, and the risk of developing AD increases with age. Biological and hormonal differences between genders, such as the decline in estrogen levels after menopause, may also contribute to the increased prevalence of AD among women.

3. Genetic Predisposition

- A small percentage of Alzheimer's cases, known as familial Alzheimer's disease (FAD), are inherited in an autosomal dominant pattern. FAD is linked to mutations in specific genes, such as the amyloid precursor protein (APP) gene and the presenilin 1 (PSEN1) and presenilin 2 (PSEN2) genes. Individuals with these genetic mutations have a nearly 100% chance of developing Alzheimer's disease, typically at a younger age, often before 65.

5. Racial and Ethnic Differences

- Alzheimer's disease prevalence varies among different racial and ethnic groups. In the United States, African Americans are approximately twice as likely to develop Alzheimer's disease compared to non-Hispanic whites, while Hispanic individuals are about 1.5 times more likely. These disparities are believed to be due to a combination of genetic, socioeconomic, and lifestyle factors, including differences in access to healthcare, education, and the prevalence of cardiovascular risk factors.

6. Geographic Factors

- The prevalence of Alzheimer's disease varies geographically, with higher rates observed in developed countries, particularly in North America and Europe. This variation may be due to differences in life expectancy, with longer life spans associated with higher rates of AD, as well as differences in diagnostic practices and awareness of the disease.

7. Lifestyle and Environmental Factors

- Cardiovascular health is closely linked to brain health, and several cardiovascular risk factors are associated with an increased risk of Alzheimer's disease. These include hypertension, diabetes, hyperlipidemia, and smoking. Lifestyle factors, such as diet and physical activity, play a significant role in the risk of developing Alzheimer's disease. Regular physical activity is also beneficial for brain health, as it promotes cardiovascular health, reduces inflammation, and supports neuroplasticity.

INGENŪ CRO

Pivotal Endpoints for Alzheimer's Disease Trials, Key Challenges and Solutions

1. Cognitive Endpoints

1.1 Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)

1.2. Mini-Mental State Examination (MMSE)

2. Functional Endpoints

2.1. Activities of Daily Living (ADL)

2.2. Clinical Dementia Rating-Sum of Boxes (CDR-SB)

3. Biomarker Endpoints

3.1. Amyloid and Tau Imaging (PET Imaging)

3.2. Cerebrospinal Fluid (CSF) Biomarkers

4. Patient-Reported Outcomes (PROs)

4.1. Quality of Life Measures

5. Neuropsychiatric Endpoints

5.1. Neuropsychiatric Inventory (NPI)

6. Global Clinical Outcome Measures

6.1. Clinical Global Impression of Change (CGIC)

1.1. Endpoint: ADAS-Cog

- The **Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)** is a widely used cognitive endpoint in Alzheimer's trials. It measures cognitive functions such as memory, language, and praxis, with higher scores indicating greater impairment.

Challenges:

- **Sensitivity to Change:** ADAS-Cog was developed primarily for mild to moderate stages of Alzheimer's. In early-stage or preclinical trials, it may lack sensitivity to detect subtle cognitive changes.
- **Floor and Ceiling Effects:** The scale can have floor effects in advanced stages, where patients score at the maximum impairment level, and ceiling effects in early stages, where patients score at minimal impairment, making it difficult to capture changes over time.
- **Variability:** The subjective nature of some assessments within ADAS-Cog can lead to variability in scoring, both across different raters and within the same rater over time

Solutions:

- **Modification and Adaptation:** Adapting ADAS-Cog to be more sensitive to early cognitive changes can improve its utility.
- **Composite Scores:** Developing composite cognitive scores that combine ADAS-Cog with other cognitive assessments could provide a more comprehensive measure of cognitive change across different stages of AD.

1.2. Endpoint: MMSE

- The **Mini-Mental State Examination (MMSE)** is a brief 30-point questionnaire widely used to assess global cognitive function. It is easy to administer and provides a quick overview of cognitive status.

Challenges:

- **Limited Sensitivity:** The MMSE may not detect mild cognitive impairment or early-stage Alzheimer's, as it focuses on broad cognitive domains.
- **Cultural and Educational Bias:** PThe MMSE can be influenced by a patient's educational level, cultural background, and language proficiency, leading to potential biases in scoring.

Solutions:

- **Supplementary Use:** Using MMSE in conjunction with other cognitive tests can help mitigate its limitations and provide a fuller picture of cognitive health.
- **Standardization Across Populations:** Ensuring culturally appropriate adaptations and translations of the MMSE can reduce bias and improve its applicability across diverse patient populations.

2.1. Endpoint: ADL

- **Activities of Daily Living (ADL) scales** measure a patient's ability to perform basic self-care tasks, such as bathing, dressing, and eating. Functional independence is a critical component of quality of life in Alzheimer's patients.

Challenges:

- **Subjectivity:** Assessments of ADL can be subjective, depending on the rater's perspective, often a caregiver or healthcare provider, which may introduce bias.
- **Variability in Decline:** The progression of functional decline can vary widely among patients, making it difficult to predict and measure consistently across a population.

Solutions:

- **Objective Measurements:** Incorporating technology, such as wearable devices and home monitoring systems, can provide more objective and continuous assessments of daily living activities.
- **Standardized Training:** Providing standardized training for caregivers and clinicians on how to accurately assess ADL can reduce subjectivity and improve reliability.

2.2. Endpoint: CDR-SB

- The **Clinical Dementia Rating-Sum of Boxes (CDR-SB)** is a composite scale that assesses both cognitive and functional domains across six categories: memory, orientation, judgment and problem-solving, community affairs, home and hobbies, and personal care.

Challenges:

- **Complexity:** The CDR-SB is more complex to administer than other scales and requires trained raters, which can limit its use in some clinical settings.
- **Rater Variability:** The scale relies heavily on the rater's judgment, which can introduce variability and affect the consistency of the results.

Solutions:

- **Training and Calibration:** Extensive training and calibration exercises for raters can help minimize variability and improve the accuracy of CDR-SB assessments.
- **Use in Combination:** Combining CDR-SB with other cognitive and functional scales can provide a more rounded assessment of a patient's condition.

3.1. Endpoint: PET Imaging

- P**ositron Emission Tomography (PET) imaging** of amyloid plaques and tau tangles has become an important biomarker endpoint in Alzheimer's trials, providing direct evidence of the underlying pathology.

Challenges:

- **Cost and Accessibility:** PET imaging is expensive and not widely available, limiting its use in large-scale clinical trials.
- **Correlation with Clinical Symptoms:** While amyloid and tau accumulation are hallmarks of Alzheimer's, their direct correlation with cognitive symptoms can be variable, especially in the early stages of the disease.

Solutions:

- **Integration with Clinical Endpoints:** Using biomarkers alongside cognitive and functional assessments can provide a more comprehensive picture of treatment effects.
- **Advancements in Imaging Technology:** Continued advancements in imaging technology may reduce costs and improve accessibility, making biomarker endpoints more feasible for broader use in trials.

3.2. Endpoint: CSF Biomarkers

- **Cerebrospinal Fluid (CSF) Biomarkers**, including amyloid-beta, tau, and phosphorylated tau, are used to assess Alzheimer's pathology. These biomarkers can be detected earlier than clinical symptoms, making them useful for early-stage trials.

Challenges:

- **Invasiveness:** The lumbar puncture procedure required to obtain CSF is invasive, which can deter patient participation and increase the complexity of the trial.
- **Standardization:** Variability in biomarker measurement techniques and interpretations across laboratories can complicate the consistency of results.

Solutions:

- **Less Invasive Alternatives:** Research into less invasive methods of biomarker detection, such as blood-based biomarkers, could improve patient participation and broaden the use of biomarkers in trials.
- **Standardized Protocols:** Developing standardized protocols for CSF collection, processing, and analysis can improve the reliability and comparability of biomarker data across different studies.

4.1. Endpoint: QoL Measures

- **Patient-reported outcomes (PROs)** assess the patient's perspective on their quality of life, including their physical, emotional, and social well-being. PROs are increasingly recognized as important endpoints in Alzheimer's trials.

Challenges:

- **Cognitive Impairment:** Alzheimer's patients may have difficulty accurately self-reporting due to cognitive impairment, which can lead to incomplete or biased data.
- **Subjectivity:** Quality of life is subjective and can vary widely based on individual expectations, experiences, and cultural factors.

Solutions:

- **Caregiver Reports:** Involving caregivers in reporting PROs can supplement patient data, especially in later stages of the disease when self-reporting becomes challenging.
- **Simplified Tools:** Developing simplified, easy-to-understand PRO tools that are specifically designed for cognitively impaired individuals can improve data quality and completeness.

5.1. Endpoint: NPI

- The **Neuropsychiatric Inventory (NPI)** is used to assess behavioral and psychological symptoms in Alzheimer's disease, such as agitation, depression, anxiety, and psychosis.

Challenges:

- **Rater Dependence:** Like many behavioral assessments, the NPI relies on caregiver or clinician ratings, which can introduce bias and variability.
- **Complexity of Symptoms:** Neuropsychiatric symptoms in Alzheimer's disease are diverse and can fluctuate, making it challenging to capture these changes consistently over time.

Solutions:

- **Standardized Assessment:** Providing rigorous training for raters and using standardized assessment protocols can help reduce variability and improve the reliability of NPI scores.
- **Frequent Monitoring:** Implementing frequent, regular monitoring of neuropsychiatric symptoms can help capture the dynamic nature of these symptoms and their response to treatment.

6.1. Endpoint: CGIC

- The Clinical Global Impression of Change (CGIC) is a global assessment tool that provides an overall impression of a patient's improvement or worsening over time, as judged by a clinician.

Challenges:

- **Subjectivity:** CGIC relies heavily on the clinician's overall judgment, which can be subjective and influenced by various factors, including the clinician's familiarity with the patient and their expectations of treatment.
- **Broad Scope:** The CGIC is broad and non-specific, which can make it less sensitive to particular aspects of cognitive or functional decline.

Solutions:

- **Structured Guidelines:** Implementing structured guidelines for CGIC assessments can help standardize the evaluation process and reduce subjectivity.
- **Combined Use:** Using CGIC in combination with more specific cognitive and functional measures can provide a balanced view of a patient's clinical status.

FDA Approved Drugs to Treat Alzheimer's Disease

Cholinesterase Inhibitors

1. Donepezil (Aricept)

- **Indication:** Approved for mild, moderate and severe Alzheimer's disease.
- **Mechanism:** Works by inhibiting the enzyme acetylcholinesterase, which breaks down acetylcholine. By preventing this breakdown, donepezil increases the level of acetylcholine in the brain, helping nerve cells communicate more effectively.
- **Side Effects:** Common side effects include nausea, diarrhea, insomnia, muscle cramps, fatigue, and loss of appetite.

2. Rivastigmine (Exelon)

- **Indication:** Approved for mild to moderate Alzheimer's disease and also for Parkinson's disease dementia.
- **Mechanism:** Inhibits acetylcholinesterase and butyrylcholinesterase, another enzyme involved in breaking down acetylcholine.
- **Administration:** Available in oral form (capsules and liquid) and as a transdermal patch, which can be easier for some patients to use.
- **Side Effects:** Gastrointestinal issues such as nausea and vomiting are common, especially when starting treatment or increasing dosage. The patch form tends to have fewer gastrointestinal side effects.

3. Galantamine (Razadyne)

- **Indication:** Approved for mild to moderate Alzheimer's disease.
- **Mechanism:** Galantamine is also a cholinesterase inhibitor, and it additionally modulates nicotinic acetylcholine receptors to increase the release of acetylcholine.
- **Side Effects:** Side effects are similar to other cholinesterase inhibitors, including gastrointestinal disturbances, dizziness, and headaches.

NMDA Receptor Antagonists

1. Memantine (Namenda)

- **Indication:** Approved for moderate to severe Alzheimer's disease.
- **Mechanism:** Memantine works by blocking NMDA receptors, which are involved in the excessive activity of glutamate, a neurotransmitter that can lead to nerve cell death when present in high amounts.
- **Side Effects:** Memantine is generally well-tolerated, but side effects can include dizziness, headache, confusion, and constipation.

2. Namzaric

- **Indication:** Approved for moderate to severe Alzheimer's disease.
- **Mechanism:** Namzaric is a combination of memantine and donepezil, offering the benefits of both drug classes in one medication.
- **Side Effects:** The side effects are a combination of those seen with memantine and donepezil, including dizziness, headache, confusion, nausea, and diarrhea.

FDA Approved Drugs to Treat Alzheimer's Disease (cont.)

Disease-Modifying Drugs

1. Aducanumab (Aduhelm)

- **Indication:** Approved for early stages of Alzheimer's (mild cognitive impairment or mild dementia).
- **Mechanism:** Aducanumab is a monoclonal antibody that targets amyloid-beta plaques in the brain, which are believed to contribute to the progression of Alzheimer's. By reducing these plaques, it is thought to slow the progression of the disease.
- **Administration:** Administered via intravenous infusion every 4 weeks.
- **Side Effects:** Common side effects include amyloid-related imaging abnormalities (ARIA), headaches, and falls. The approval of aducanumab has been controversial due to mixed results in clinical trials regarding its effectiveness.

2. Lecanemab (Leqembi)

- **Indication:** Approved for early Alzheimer's (mild cognitive impairment or mild dementia).
- **Mechanism:** Lecanemab is another monoclonal antibody that targets soluble and insoluble forms of amyloid-beta. It is designed to slow cognitive decline in patients with early Alzheimer's.
- **Administration:** Administered via intravenous infusion every two weeks.
- **Side Effects:** Similar to aducanumab, including ARIA, infusion-related reactions, and a small risk of more serious side effects like brain swelling or microhemorrhages.

New approved FDA drug in 2024

Kisunla is a new addition to the list of FDA-approved Alzheimer's drugs, having received approval in July 2024. Due to its recent approval, it may not yet be as widely recognized as the other medications, but it represents a significant advancement in Alzheimer's treatment.

Key Information about Kisunla:

- **Mechanism:** Kisunla is an amyloid-targeting therapy, designed to help the immune system clear amyloid-beta plaques from the brain. This is believed to slow the progression of Alzheimer's disease.
- **Administration:** The drug is administered via intravenous infusion every four weeks, with the initial doses at 700 mg and subsequent doses at 1400 mg.
- **Side Effects:** Common side effects include amyloid-related imaging abnormalities (ARIA), which can manifest as brain swelling or microhemorrhages. These side effects are monitored through regular MRI scans. Other side effects include headache, infusion-related reactions, and potential allergic reactions.

Top 5 Most Commonly Prescribed Drugs for Alzheimer's Disease

Drug Name	Year of Approval	Sponsor	Mechanism of Action	Therapeutic Effects
Aricept (Donepezil)	1996	Eisai/Pfizer	Acetylcholinesterase inhibitor	Improves cognition and function by increasing acetylcholine levels in the brain. Used for mild, moderate, and severe Alzheimer's disease.
Namenda (Memantine)	2003	Allergan	NMDA receptor antagonist	Regulates glutamate activity to prevent neurotoxicity, used to treat moderate to severe Alzheimer's disease by improving cognition and daily function.
Exelon (Rivastigmine)	2000	Novartis	Acetylcholinesterase inhibitor	Increases acetylcholine levels in the brain, helping to improve cognitive function and behavioral symptoms in mild to moderate Alzheimer's disease.
Razadyne (Galantamine)	2001	Janssen	Acetylcholinesterase inhibitor and modulator of nicotinic receptors	Enhances cholinergic function by increasing acetylcholine and modulating nicotinic receptors, improving cognition in mild to moderate Alzheimer's disease.
Namzaric (Combination drug: Memantine and Donepezil)	2014	Allergan	Combination of NMDA receptor antagonist and acetylcholinesterase inhibitor	Combines the mechanisms of memantine and donepezil to treat moderate to severe Alzheimer's disease by improving cognition and function.

Pivotal Trials that Demonstrated the efficacy of FDA Approved Drugs

Drug Name	Clinical Identifier/Journal	Sample Size	Key Findings and Statistical Data
Aricept (Donepezil)	Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease.	473 participants	**Cognitive and Global Function Improvement:** The study found that donepezil significantly improved cognitive function and global clinical ratings in patients with mild to moderate Alzheimer's disease. These benefits were observed at multiple time points (weeks 12, 18, and 24) and were measured using the ADAS-cog and CIBIC plus scales. **Side Effects and Treatment Sustainability:** Donepezil was generally well-tolerated, with mild and transient cholinergic side effects such as diarrhea, nausea, and vomiting, more commonly reported at the higher 10 mg/d dose. However, the cognitive and global function improvements were not sustained after a 6-week washout period, indicating the effects of the drug diminish after discontinuation.
Namenda (Memantine)	Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Möbius HJ. Memantine in moderate-to-severe Alzheimer's disease.	252 participants	**Efficacy in Cognitive and Functional Outcomes:** Patients treated with memantine showed statistically significant improvements in cognitive function and daily living activities compared to those receiving placebo. This was evident from the outcomes on the Severe Impairment Battery (SIB) and the Alzheimer's Disease Cooperative Study–Activities of Daily Living Inventory (ADCS-ADLsev), with significant improvements noted in both observed cases and last observation carried forward analyses. **Safety and Tolerability:** Memantine was generally well-tolerated, with no significant increase in adverse events compared to the placebo group. The study reported a lower rate of treatment discontinuation in the memantine group compared to the placebo group, indicating good patient tolerance of the drug.
Exelon (Rivastigmine)	Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease.	699 participants	**Efficacy in Treating Alzheimer's Disease:** The study demonstrated that high-dose rivastigmine (6-12 mg/day) significantly improved cognitive function, global assessment of change, activities of daily living, and disease severity in patients with mild to moderately severe Alzheimer's disease. These improvements were measured using the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog), Clinician's Interview-Based Impression of Change-Plus (CIBIC-Plus), and Progressive Deterioration Scale (PDS). **Safety and Tolerability:** Rivastigmine was generally well-tolerated, with the most common side effects being gastrointestinal in nature, including nausea and vomiting. These side effects were mild to moderate in intensity and self-limited.
Razadyne (Galantamine)	Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD.	978 participants	**Efficacy:** Galantamine treatment (16 mg/day and 24 mg/day) significantly improved cognitive function as measured by the ADAS-cog score, with differences of 3.3 and 3.6 points respectively, compared to placebo ($p < 0.001$). It also led to better outcomes in daily activities and behavioral symptoms. **Safety:** Treatment discontinuations due to adverse events were low and similar between the galantamine groups (6-10%) and the placebo group (7%). The incidence of adverse events, particularly gastrointestinal symptoms, was low and mostly mild across all groups.
Namzaric (Memantine and Donepezil)	*The FDA approval for Namzaric was based on clinical trials that had already established the efficacy and safety of its individual components, memantine and donepezil.*		

Approved Product Analysis: Aricept

14.1. Mild to Moderate Alzheimer's Disease – Alzheimer's disease (diagnosed by NINCDS and DSM III-R criteria, MiniMental State Examination ≥ 10 and ≤ 26 and Clinical Dementia Rating of 1 or 2)

Thirty-Week Study

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Alzheimer's Disease patients	Cognitive function in Alzheimer's Disease patients	ADAS-cog (Alzheimer's Disease Assessment Scale-Cognitive subscale)	24 weeks (double-blind), 30 weeks (with 6-week washout)	N=473 (Placebo, Aricept 5 mg/day, Aricept 10 mg/day)	After 24 weeks, mean differences in ADAS-cog change scores were 2.8 points (5 mg/day) and 3.1 points (10 mg/day) vs. placebo. No significant difference between 5 mg/day and 10 mg/day doses. The beneficial effects of ARICEPT diminish within 6 weeks after discontinuation, returning to placebo levels, indicating no lasting change in the underlying disease.
Alzheimer's Disease patients	Global clinical status in Alzheimer's Disease patients	CIBIC-plus (Clinician's Interview-Based Impression of Change plus caregiver input)	24 weeks	N=473 (Placebo, Aricept 5 mg/day, Aricept 10 mg/day)	Mean differences in CIBIC-plus scores were 0.35 points (5 mg/day) and 0.39 points (10 mg/day) vs. placebo. No significant difference between 5 mg/day and 10 mg/day doses.

Fifteen-Week Study

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Alzheimer's Disease patients	Cognitive function in Alzheimer's Disease patients	ADAS-cog (Alzheimer's Disease Assessment Scale-Cognitive subscale)	12 weeks, 15 weeks (with 3-week washout)	Not specified, but data implies significant sample sizes	After 12 weeks, mean differences in ADAS-cog change scores were 2.7 points (5 mg/day) and 3.0 points (10 mg/day) vs. placebo. No significant difference between 5 mg/day and 10 mg/day doses. Following 3-week placebo washout, ADAS-cog scores returned to near-baseline levels, indicating loss of treatment effect.
Alzheimer's Disease patients	Global clinical status in Alzheimer's Disease patients	CIBIC-plus (Clinician's Interview-Based Impression of Change plus caregiver input)	12 weeks	Not specified, but data implies significant sample sizes	Mean differences in CIBIC-plus scores were 0.36 points (5 mg/day) and 0.38 points (10 mg/day) vs. placebo. Both differences were statistically significant.

Approved Product Analysis: Aricept（cont.）

14.2. Moderate to Severe Alzheimer's Disease

Swedish 6-Month Study – Alzheimer's disease diagnosed by NINCDS-ADRDA and DSM-IV criteria, MMSE: range of 1-10

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Severe Alzheimer's Disease patients	Cognitive function in severe Alzheimer's Disease patients	SIB (Severe Impairment Battery)	6 months	N=248 (Aricept: 5 mg/day for 28 days, then 10 mg/day; Placebo)	At 6 months, the mean difference in SIB change scores was 5.9 points in favor of Aricept vs. placebo, indicating statistically significant improvement.
Severe Alzheimer's Disease patients	Daily functional capabilities in severe Alzheimer's Disease patients	ADCS-ADL-severe (Activities of Daily Living - Severe)	6 months	N=248 (Aricept: 5 mg/day for 28 days, then 10 mg/day; Placebo)	At 6 months, the mean difference in ADCS-ADL-severe change scores was 1.8 points in favor of Aricept vs. placebo, showing statistically significant improvement.

Japanese 24-Week Study

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Severe Alzheimer's Disease patients	Cognitive function in severe Alzheimer's Disease patients	SIB (Severe Impairment Battery)	24 weeks	N=325 (Donepezil 5 mg/day, Donepezil 10 mg/day, Placebo)	Statistically significant improvement in SIB scores for both 5 mg/day and 10 mg/day doses of donepezil vs. placebo.
Severe Alzheimer's Disease patients	Global clinical status in severe Alzheimer's Disease patients	CIBIC-plus (Clinician's Interview-Based Impression of Change plus caregiver input)	24 weeks	N=325 (Donepezil 5 mg/day, Donepezil 10 mg/day, Placebo)	Statistically significant improvement in CIBIC-plus scores for 10 mg/day dose of donepezil vs. placebo. No significant difference for 5 mg/day dose vs. placebo.

Approved Product Analysis: Aricept (cont.)

Study of 23 mg/day – Alzheimer's disease diagnosed by NINCDS-ADRDA and DSM-IV criteria, MMSE: range of 0-20

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Moderate to severe Alzheimer's Disease patients	Cognitive function in moderate to severe Alzheimer's Disease patients	SIB (Severe Impairment Battery)	24 weeks	N=1434 (Aricept 23 mg/day vs. 10 mg/day)	At 24 weeks, the LS mean difference in SIB change scores was 2.2 points in favor of Aricept 23 mg/day vs. 10 mg/day, showing statistically significant improvement (p = 0.0001).
Moderate to severe Alzheimer's Disease patients	Global clinical status in moderate to severe Alzheimer's Disease patients	CIBIC-plus (Clinician's Interview-Based Impression of Change plus caregiver input)	24 weeks	N=1434 (Aricept 23 mg/day vs. 10 mg/day)	The mean difference between the 23 mg/day and 10 mg/day treatment groups was 0.06 units. This difference was not statistically significant.

Approved Product Analysis: Namenda

Study 1 (Twenty-Eight-Week Study) – Alzheimer's disease (diagnosed by DSM-IV and NINCDS-ADRDA criteria, with Mini-Mental State Examination scores ≥ 3 and ≤ 14 and Global Deterioration Scale Stages 5-6)

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Moderate to severe Alzheimer's Disease patients	Daily functional capabilities in moderate to severe Alzheimer's Disease patients	ADCS-ADL (Alzheimer's Disease Cooperative Study Activities of Daily Living)	28 weeks	N=252 (Namenda: 20 mg/day; Placebo)	At 28 weeks, the mean difference in ADCS-ADL change scores was 3.4 points in favor of Namenda vs. placebo, showing statistically significant superiority of Namenda.
Moderate to severe Alzheimer's Disease patients	Cognitive function in moderate to severe Alzheimer's Disease patients	SIB (Severe Impairment Battery)	28 weeks	N=252 (Namenda: 20 mg/day; Placebo)	At 28 weeks, the mean difference in SIB change scores was 5.7 points in favor of Namenda vs. placebo, indicating statistically significant improvement.

Study 2 (Twenty-Four-Week Study) – Alzheimer's disease (diagnosed by NINCDS-ADRDA criteria, with Mini-Mental State Examination scores ≥ 5 and ≤ 14)

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Moderate to severe Alzheimer's Disease patients	Daily functional capabilities in moderate to severe Alzheimer's Disease patients	ADCS-ADL (Alzheimer's Disease Cooperative Study Activities of Daily Living)	24 weeks	N=404 (Namenda/Donepezil vs. Placebo/Donepezil)	At 24 weeks, the mean difference in ADCS-ADL change scores was 1.6 points in favor of Namenda/Donepezil vs. Placebo/Donepezil, showing statistically significant superiority of the combination therapy.
Moderate to severe Alzheimer's Disease patients	Cognitive function in moderate to severe Alzheimer's Disease patients	SIB (Severe Impairment Battery)	24 weeks	N=404 (Namenda/Donepezil vs. Placebo/Donepezil)	At 24 weeks, the mean difference in SIB change scores was 3.3 points in favor of Namenda/Donepezil vs. Placebo/Donepezil, indicating statistically significant improvement.

Approved Product Analysis: Namenda (cont.)

Study 3 (Twelve-Week Study) – Dementia according to DSM-III-R, a Mini-Mental State Examination score of < 10, and Global Deterioration Scale staging of 5 to 7

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Patients with dementia	Day-to-day functional capabilities in patients with dementia	Care Dependency Subscale of the Behavioral Rating Scale for Geriatric Patients (BGP)	12 weeks	N=166 (Namenda vs. Placebo)	Statistically significant improvement in day-to-day functioning in favor of Namenda compared to placebo.
Patients with dementia	Overall clinical effect in patients with dementia	Clinical Global Impression of Change (CGI-C)	12 weeks	N=166 (Namenda vs. Placebo)	Statistically significant improvement in overall clinical effect in favor of Namenda compared to placebo.

Approved Product Analysis: Exelon

International 24-Week Study of Exelon Patch (rivastigmine transdermal system) – Alzheimer's Disease [diagnosed by NINCDSADRDA and DSM-IV criteria, Mini-Mental Status Examination (MMSE) score ≥ 10 and ≤ 20

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Alzheimer's Disease patients	Cognitive function in Alzheimer's Disease patients	ADAS-Cog (Alzheimer's Disease Assessment Scale-Cognitive subscale)	24 weeks (16-week titration phase followed by an 8-week maintenance phase)	N=1195 (Exelon Patch 9.5 mg/24h, Exelon Patch 17.4 mg/24h, Exelon capsules 6 mg BID, Placebo)	Mean differences in ADAS-Cog change scores: 1.8 units (Patch 9.5 mg/24h), 2.9 units (Patch 17.4 mg/24h), 1.8 units (Capsules 6 mg BID) vs. placebo, all statistically significant.
Alzheimer's Disease patients	Overall clinical effect in Alzheimer's Disease patients	ADCS-CGIC (Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change)	24 weeks (16-week titration phase followed by an 8-week maintenance phase)	N=1195 (Exelon Patch 9.5 mg/24h, Exelon Patch 17.4 mg/24h, Exelon capsules 6 mg BID, Placebo)	Mean difference in ADCS-CGIC scores: 0.2 units in favor of Exelon-treated groups vs. placebo, statistically significant.

Approved Product Analysis: Razadyne

14.2 Immediate-Release Tablets

U.S. Twenty-One Week Fixed-Dose Study – Alzheimer's disease [diagnosed by NINCDS-ADRDA criteria, with Mini-Mental State Examination scores that were ≥10 and ≤24]

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Alzheimer's Disease patients	Cognitive function in Alzheimer's Disease patients	ADAS-cog (Alzheimer's Disease Assessment Scale-Cognitive subscale)	21 weeks	N=978 (Galantamine 8 mg/day, 16 mg/day, 24 mg/day, Placebo)	Mean differences in ADAS-cog change scores: 1.7 units (8 mg/day), 3.3 units (16 mg/day), 3.6 units (24 mg/day) vs. placebo. The 16 mg/day and 24 mg/day treatments were statistically significantly superior to placebo and the 8 mg/day dose.
Alzheimer's Disease patients	Overall clinical effect in Alzheimer's Disease patients	CIBIC-plus (Clinician's Interview-Based Impression of Change plus caregiver input)	21 weeks	N=978 (Galantamine 8 mg/day, 16 mg/day, 24 mg/day, Placebo)	Mean differences in CIBIC-plus scores: 0.15 units (8 mg/day), 0.41 units (16 mg/day), 0.44 units (24 mg/day) vs. placebo. The 16 mg/day and 24 mg/day treatments were statistically significantly superior to placebo and to the 8 mg/day dose.

U.S. Twenty-Six Week Fixed-Dose Study

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Alzheimer's Disease patients	Cognitive function in Alzheimer's Disease patients	ADAS-cog (Alzheimer's Disease Assessment Scale-Cognitive subscale)	26 weeks(3-week dose titration phase and a 23-week maintenance phase)	N=636 (Galantamine 24 mg/day, 32 mg/day, Placebo)	Mean differences in ADAS-cog change scores: 3.9 units (24 mg/day) and 3.8 units (32 mg/day) vs. placebo. Both doses were statistically significantly superior to placebo, with no significant difference between the 24 mg/day and 32 mg/day groups.
Alzheimer's Disease patients	Overall clinical effect in Alzheimer's Disease patients	CIBIC-plus (Clinician's Interview-Based Impression of Change plus caregiver input)	26 weeks(3-week dose titration phase and a 23-week maintenance phase)	N=636 (Galantamine 24 mg/day, 32 mg/day, Placebo)	Mean differences in CIBIC-plus scores: 0.28 units (24 mg/day) and 0.29 units (32 mg/day) vs. placebo. Both treatments were statistically significantly superior to placebo, with no significant difference between the two dose groups.

Approved Product Analysis: Razadyne (cont.)

14.2 Immediate-Release Tablets (cont.)

International Twenty-Six Week Fixed-Dose Study

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Alzheimer's Disease patients	Cognitive function in Alzheimer's Disease patients	ADAS-cog (Alzheimer's Disease Assessment Scale-Cognitive subscale)	26 weeks (3-week dose titration phase and a 23-week maintenance phase)	N=653 (Galantamine 24 mg/day, 32 mg/day, Placebo)	Mean differences in ADAS-cog change scores: 3.1 units (24 mg/day) and 4.1 units (32 mg/day) vs. placebo. Both treatments were statistically significantly superior to placebo, with no significant difference between the 24 mg/day and 32 mg/day groups.
Alzheimer's Disease patients	Overall clinical effect in Alzheimer's Disease patients	CIBIC-plus (Clinician's Interview-Based Impression of Change plus caregiver input)	26 weeks (3-week dose titration phase and a 23-week maintenance phase)	N=653 (Galantamine 24 mg/day, 32 mg/day, Placebo)	Mean differences in CIBIC-plus scores: 0.34 units (24 mg/day) and 0.47 units (32 mg/day) vs. placebo. Both treatments were statistically significantly superior to placebo, with no significant difference between the two dose groups.

International Thirteen-Week Flexible-Dose Study

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Alzheimer's Disease patients	Cognitive function in Alzheimer's Disease patients	ADAS-cog (Alzheimer's Disease Assessment Scale-Cognitive subscale)	13 weeks (3-week dose titration phase and a 10-week maintenance phase)	N=386 (Galantamine 24-32 mg/day vs. Placebo)	At 13 weeks, the mean difference in ADAS-cog change scores was 1.9 units in favor of galantamine compared to placebo, showing statistically significant improvement.
Alzheimer's Disease patients	Overall clinical effect in Alzheimer's Disease patients	CIBIC-plus (Clinician's Interview-Based Impression of Change plus caregiver input)	13 weeks (3-week dose titration phase and a 10-week maintenance phase)	N=386 (Galantamine 24-32 mg/day vs. Placebo)	The mean difference in CIBIC-plus scores between galantamine and placebo was 0.37 units, indicating statistically significant superiority of galantamine.

Approved Product Analysis: Razadyne (cont.)

14.3 Extended-Release Capsules

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Alzheimer's Disease patients	Cognitive function in Alzheimer's Disease patients	ADAS-cog (Alzheimer's Disease Assessment Scale-Cognitive subscale)	6 months	Not specified (Galantamine extended-release capsules 16-24 mg/day, Galantamine tablets 8-12 mg BID, Placebo)	The effects of both galantamine extended-release capsules and galantamine tablets on the ADAS-cog, CIBIC-plus, and ADCS-ADL were similar in this study.
Alzheimer's Disease patients	Overall clinical effect in Alzheimer's Disease patients	CIBIC-plus (Clinician's Interview-Based Impression of Change plus caregiver input)	6 months	Not specified (Galantamine extended-release capsules 16-24 mg/day, Galantamine tablets 8-12 mg BID, Placebo)	The effects of both galantamine extended-release capsules and galantamine tablets on the ADAS-cog, CIBIC-plus, and ADCS-ADL were similar in this study.
Alzheimer's Disease patients	Functional capabilities in Alzheimer's Disease patients	ADCS-ADL (Alzheimer's Disease Cooperative Study-Activities of Daily Living)	6 months	Not specified (Galantamine extended-release capsules 16-24 mg/day, Galantamine tablets 8-12 mg BID, Placebo)	The effects of both galantamine extended-release capsules and galantamine tablets on the ADAS-cog, CIBIC-plus, and ADCS-ADL were similar in this study.

Approved Product Analysis: Namzaric

24-week Study of Memantine Hydrochloride Extended-Release – Alzheimer's disease (diagnosed by DSM-IV criteria and NINCDS-ADRDA criteria for AD with a Mini Mental State Examination [MMSE] score ≥ 3 and ≤ 14 at Screening and Baseline)

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Alzheimer's Disease patients	Cognitive function in Alzheimer's Disease patients	SIB (Severe Impairment Battery)	24 weeks	N=677 (Memantine HCl ER 28 mg/day + AChEI vs. Placebo + AChEI)	Mean difference in SIB change scores: 2.6 units in favor of memantine HCl ER 28 mg/AChEI vs. placebo/AChEI, indicating statistically significant superiority.
Alzheimer's Disease patients	Overall clinical effect in Alzheimer's Disease patients	CIBIC-plus (Clinician's Interview-Based Impression of Change plus caregiver input)	24 weeks	N=677 (Memantine HCl ER 28 mg/day + AChEI vs. Placebo + AChEI)	Mean difference in CIBIC-plus scores: 0.3 units in favor of memantine HCl ER 28 mg/AChEI vs. placebo/AChEI, showing statistically significant improvement.
Alzheimer's Disease patients on Donepezil	Cognitive function in Alzheimer's Disease patients on Donepezil	SIB (Severe Impairment Battery)	24 weeks	Subset of 68% of N=677 (Memantine HCl ER 28 mg/day + Donepezil vs. Placebo + Donepezil)	Mean difference in SIB change scores: 2.7 units in favor of memantine HCl ER 28 mg + Donepezil, similar to the overall study population.
Alzheimer's Disease patients on Donepezil	Overall clinical effect in Alzheimer's Disease patients on Donepezil	CIBIC-plus (Clinician's Interview-Based Impression of Change plus caregiver input)	24 weeks	Subset of 68% of N=677 (Memantine HCl ER 28 mg/day + Donepezil vs. Placebo + Donepezil)	Mean difference in CIBIC-plus scores: 0.3 units in favor of memantine HCl ER 28 mg + Donepezil, similar to the overall study population.

Approved Product Analysis: Namzaric

6-Month Study of Donepezil Hydrochloride – Alzheimer's disease diagnosed by NINCDS-ADRDA and DSMIV criteria, MMSE: range of 1-10

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Severe Alzheimer's Disease patients	Cognitive function in severe Alzheimer's Disease patients	SIB (Severe Impairment Battery)	6 months	N=248 (Donepezil 10 mg/day vs. Placebo)	Mean difference in SIB change scores: 5.9 points in favor of donepezil vs. placebo, indicating statistically significant superiority.
Severe Alzheimer's Disease patients	Functional capabilities in severe Alzheimer's Disease patients	ADCS-ADL-severe (Modified Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory for Severe Alzheimer's Disease)	6 months	N=248 (Donepezil 10 mg/day vs. Placebo)	Mean difference in ADCS-ADL-severe change scores: 1.8 points in favor of donepezil vs. placebo, indicating statistically significant improvement.

24-Week Study of Donepezil Hydrochloride

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Severe Alzheimer's Disease patients	Cognitive function in severe Alzheimer's Disease patients	SIB (Severe Impairment Battery)	24 weeks	N=325 (Donepezil 5 mg/day, Donepezil 10 mg/day, Placebo)	Statistically significant improvement in SIB scores for both 5 mg/day and 10 mg/day doses of donepezil vs. placebo.
Severe Alzheimer's Disease patients	Overall clinical effect in severe Alzheimer's Disease patients	CIBIC-plus (Clinician's Interview-Based Impression of Change plus caregiver input)	24 weeks	N=325 (Donepezil 5 mg/day, Donepezil 10 mg/day, Placebo)	Statistically significant improvement in CIBIC-plus scores for 10 mg/day dose of donepezil vs. placebo. No significant difference for the 5 mg/day dose vs. placebo.

Approved Product Analysis: Aduhelm

Study 1

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Patients with Alzheimer's disease (Stages 3 & 4)	Clinical Efficacy	CDR-Sum of Boxes (CDR-SB)	78 weeks	ADUHELM High dose: N=547, Placebo: N=548	-0.39 (-22%) vs. Placebo (p=0.0120)
Patients with Alzheimer's disease (Stages 3 & 4)	Cognitive Function	MMSE	78 weeks	ADUHELM High dose: N=547, Placebo: N=548	-0.6 (-18%) vs. Placebo (p=0.0493)
Patients with Alzheimer's disease (Stages 3 & 4)	Cognitive Function	ADAS-Cog 13	78 weeks	ADUHELM High dose: N=547, Placebo: N=548	-1.4 (-27%) vs. Placebo (p=0.0097)
Patients with Alzheimer's disease (Stages 3 & 4)	Daily Living Activities	ADCS-ADL-MCI	78 weeks	ADUHELM High dose: N=547, Placebo: N=548	1.7 (-4.0%) vs. Placebo (p=0.0006)
Patients with Alzheimer's disease (Stages 3 & 4)	Neuropsychiatric Symptoms	NPI-10	78 weeks	ADUHELM High dose: N=547, Placebo: N=548	-1.3 (-87%) vs. Placebo (p=0.0215)
Subgroup of Patients (Amyloid PET substudy)	Amyloid Plaque Reduction	Amyloid Beta PET Composite SUVR	78 weeks	ADUHELM High dose: N=170, Placebo: N=159	-0.278 (-20.2%) vs. Placebo (p<0.0001)
Subgroup of Patients (Amyloid PET substudy)	Amyloid Plaque Reduction	Amyloid Beta PET Centiloid	78 weeks	ADUHELM High dose: N=170, Placebo: N=159	-64.2 (-60.8%) vs. Placebo (p<0.0001)
Subgroup of Patients (CSF biomarker substudy)	Tau Protein Reduction	CSF P-Tau (pg/mL)	78 weeks	ADUHELM High dose: N=17, Placebo: N=28	-22.4 vs. Placebo (p=0.0005)
Subgroup of Patients (CSF biomarker substudy)	Tau Protein Reduction	CSF T-Tau (pg/mL)	78 weeks	ADUHELM High dose: N=17, Placebo: N=28	-112.05 vs. Placebo (p=0.0088)

Approved Product Analysis: Aduhelm (cont.)

Study 2

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Patients with Alzheimer's disease (Stages 3 & 4)	Primary Endpoint	CDR-Sum of Boxes (CDR-SB)	78 weeks	ADUHELM High dose: N=551, Placebo: N=543	No statistically significant difference (data not shown)
Subgroup of Patients (Amyloid PET substudy)	Biomarker Endpoints	Amyloid Beta PET Composite SUVR	78 weeks	ADUHELM High dose: N=183, Placebo: N=204	-0.232 (-16.9%) vs. Placebo (p<0.0001)
Subgroup of Patients (Amyloid PET substudy)	Biomarker Endpoints	Amyloid Beta PET Centiloid	78 weeks	ADUHELM High dose: N=183, Placebo: N=204	-54.0 (-59%) vs. Placebo (p<0.0001)
Subgroup of Patients (CSF biomarker substudy)	Biomarker Endpoints	CSF P-Tau (pg/mL)	78 weeks	ADUHELM High dose: N=18, Placebo: N=15	-13.19 (-10.9%) vs. Placebo (p=0.3019)
Subgroup of Patients (CSF biomarker substudy)	Biomarker Endpoints	CSF T-Tau (pg/mL)	78 weeks	ADUHELM High dose: N=16, Placebo: N=14	-69.25 (-11.7%) vs. Placebo (p=0.3098)

Study 3

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Patients with Alzheimer's disease (Stages 3 & 4)	Primary Endpoint (Exploratory)	CDR-Sum of Boxes (CDR-SB)	54 weeks	ADUHELM 10 mg/kg: N=32, Placebo: N=48	Directional alignment with Study 1 (CDR-SB: -1.26 vs. placebo)
Subgroup of Patients (Amyloid PET substudy)	Biomarker Endpoints	Amyloid Beta PET Composite SUVR	54 weeks	ADUHELM 10 mg/kg: N=28, Placebo: N=42	-0.277 (-19.2%) vs. Placebo (p<0.0001)
Subgroup of Patients (Amyloid PET substudy)	Biomarker Endpoints	Amyloid Beta PET Centiloid	54 weeks	ADUHELM 10 mg/kg: N=28, Placebo: N=42	-61.1 (-61%) vs. Placebo (p<0.0001)

Approved Product Analysis: Leqembi

Study 1

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Patients with Alzheimer's disease (Stages 3 & 4)	Cognitive Function	Composite Score (CDR-SB, MMSE, ADAS-Cog 14)	53 weeks	LEQEMBI 10 mg/kg: N=161, Placebo: N=247	64% likelihood of ≥25% slowing of progression (did not meet prespecified success criterion)
Patients with Alzheimer's disease (Stages 3 & 4)	Amyloid Plaque Reduction	Amyloid Beta PET Composite SUVR	79 weeks	LEQEMBI 10 mg/kg: N=44, Placebo: N=98	-0.310 vs. Placebo (p<0.0001)
Patients with Alzheimer's disease (Stages 3 & 4)	Amyloid Plaque Reduction	Amyloid Beta PET Centiloid	79 weeks	LEQEMBI 10 mg/kg: N=44, Placebo: N=98	-73.5 vs. Placebo (p<0.0001)
Patients with Alzheimer's disease (Stages 3 & 4)	Cognitive Function	CDR-Sum of Boxes (CDR-SB)	79 weeks	LEQEMBI 10 mg/kg: N=161, Placebo: N=247	-0.40 (-26%) relative to placebo (90% CI: -0.82, 0.03)
Patients with Alzheimer's disease (Stages 3 & 4)	Cognitive Function	ADAS-Cog 14	79 weeks	LEQEMBI 10 mg/kg: N=161, Placebo: N=247	-2.31 (-47%) relative to placebo (90% CI: -3.91, -0.72)

Study 2

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Patients with Alzheimer's disease (Stages 3 & 4)	Cognitive Function	CDR-Sum of Boxes (CDR-SB)	18 months	LEQEMBI 10 mg/kg: N=859, Placebo: N=875	-0.45 (-27%) vs. Placebo (p<0.0001)
Patients with Alzheimer's disease (Stages 3 & 4)	Cognitive Function	ADAS-Cog 14	18 months	LEQEMBI 10 mg/kg: N=854, Placebo: N=872	-1.42 (-26%) vs. Placebo (p<0.00065)
Patients with Alzheimer's disease (Stages 3 & 4)	Daily Living Activities	ADCS MCI-ADL	18 months	LEQEMBI 10 mg/kg: N=783, Placebo: N=796	3.5 (+37%) vs. Placebo (p<0.0001)

Approved Product Analysis: Kisunla

Study 1

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Patients with Alzheimer's disease (Stages 3 & 4)	Cognitive and Functional Performance	Integrated Alzheimer's Disease Rating Scale (iADRS)	76 weeks	Combined Population: N=1736	2.92 improvement vs. placebo in combined population (p<0.0001)
Patients with Alzheimer's disease (Stages 3 & 4)	Cognitive Function	CDR-Sum of Boxes (CDR-SB)	76 weeks	KISUNLA: N=860, Placebo: N=876	-0.70 (-29%) vs. Placebo (p<0.0001)
Patients with Alzheimer's disease (Stages 3 & 4)	Cognitive Function	ADAS-Cog 13	76 weeks	KISUNLA: N=860, Placebo: N=876	-1.33 (-20%) vs. Placebo (p=0.0006)
Patients with Alzheimer's disease (Stages 3 & 4)	Daily Living Activities	ADCS-iADL	76 weeks	KISUNLA: N=860, Placebo: N=876	1.70 (+28%) vs. Placebo (p=0.0001)

Summary of Failed Drug Candidates for Alzheimer's Disease

Name of Drug	Clinical Trial Identifier	Reason for Termination / Drug Failure	Trend Analysis
Lipitor	NCT00151502	It was found that atorvastatin with donepezil compared to placebo with donepezil was not associated with significant benefit on cognition and global function measures over 72 weeks in subjects with mild to moderate Alzheimer's disease (AD).	This reflects a broader trend where cholesterol-lowering drugs, initially hypothesized to have neuroprotective effects, failed to show efficacy in clinical trials for Alzheimer's. This suggests that targeting cholesterol pathways might not be effective in altering the course of Alzheimer's disease, leading to a shift in focus towards other therapeutic targets like amyloid plaques and tau proteins.
Nelonicline	NCT01690195	Lack of Efficacy - ABT-126 at a dose of 75mg did not demonstrate significant improvement compared with placebo in the primary efficacy endpoint.	Nelonicline's failure due to lack of efficacy is part of a recurring pattern in Alzheimer's research, where drugs targeting nicotinic acetylcholine receptors have struggled to demonstrate significant cognitive benefits. Despite promising preclinical data, these agents often do not translate into meaningful clinical improvements, reflecting the complexity of the disease and the challenge of targeting the cholinergic system in Alzheimer's.
Pozanicline	NCT00555204	Lack of Efficacy- ABT-089 was not efficacious in mild to moderate Alzheimer disease when administered as adjunctive therapy to acetylcholinesterase inhibitors.	This trend highlights the difficulties in developing adjunct therapies that effectively enhance the benefits of existing treatments.
Gosuranemab	NCT03352557	The trial was terminated due to lack of efficacy following the placebo-controlled period readout.	While tau pathology is a hallmark of Alzheimer's, interventions aimed at modifying tau have repeatedly fallen short in clinical trials. This suggests that tau-targeted therapies alone may not be sufficient to alter disease progression, and combination therapies or earlier intervention may be required.
Solanezumab	NCT00904683	Although findings suggest that solanezumab was generally well tolerated, but it was not effective in improving cognition or functional ability in the treatment of subjects with Alzheimer's disease.	The repeated failures of amyloid-targeting therapies in clinical trials led to a re-evaluation of the amyloid hypothesis. Though failing to meet primary endpoints, this trial proved successful secondary endpoints reading towards Aducanumab.

Common Failure Points in Clinical Trials for Alzheimer's Disease

Clinical trials for Alzheimer's disease have faced significant challenges and a high rate of failure, particularly in the late stages of development. The unique pathophysiology of Alzheimer's, the complexity of its progression, and the limitations of current research methodologies contribute to these.

1. Target Engagement and Pathophysiological Complexity:

Alzheimer's is characterized by complex pathophysiological changes, including the accumulation of amyloid-beta plaques and tau protein tangles, chronic neuroinflammation, synaptic loss, and neuronal death. These diverse, interrelated targets make it challenging to identify the most effective intervention.

2. Patient Selection and Population Heterogeneity:

Alzheimer's disease is a heterogeneous condition, with variations in disease progression, genetic background, and comorbidities among patients. This heterogeneity poses significant challenges in patient selection for clinical trials.

3. Cognitive Decline and Endpoint Measurement:

Measuring cognitive decline and other clinical endpoints in Alzheimer's disease trials is fraught with challenges. Traditional endpoints, such as the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) and the Clinical Dementia Rating-Sum of Boxes (CDR-SB), are widely used but have limitations.

4. Statistical and Methodological Challenges:

The design and analysis of Alzheimer's disease trials present several unique statistical and methodological challenges:

- High Placebo Response
- Adaptive Trial Designs
- Longitudinal Data Analysis

5. Drug Delivery and Blood-Brain Barrier Challenges:

The delivery of therapeutic agents to the brain presents another significant challenge in Alzheimer's disease trials. The blood-brain barrier (BBB) is a selective barrier that prevents most large molecules and many small molecules from entering the brain.

6. Safety Concerns and Adverse Effects:

The safety profile of investigational drugs in Alzheimer's disease is a critical consideration, particularly given the vulnerable population of elderly patients who often have multiple comorbidities.

Safety Concerns for Alzheimer's Disease

1. Adverse Effects of Drug Treatments:

Cholinesterase Inhibitors

- Drugs: Donepezil (Aricept), Rivastigmine (Exelon), Galantamine (Razadyne)
- Common Side Effects: These medications increase acetylcholine levels in the brain to improve cognition, but they often cause gastrointestinal issues such as nausea, vomiting, and diarrhea. Other side effects can include muscle cramps, insomnia, and fatigue.
- Serious Concerns: In some cases, cholinesterase inhibitors can cause bradycardia (slow heart rate) or exacerbate existing respiratory conditions like asthma or chronic obstructive pulmonary disease (COPD). The risk of these side effects must be carefully managed, particularly in patients with pre-existing heart or lung conditions.

NMDA Receptor Antagonist

- Drug: Memantine (Namenda)
- Common Side Effects: Memantine, which works by modulating the glutamate system to protect against neurotoxicity, can cause dizziness, headache, constipation, and confusion. These side effects can significantly impact the quality of life, especially in older adults.
- Serious Concerns: Memantine has been associated with hypertension, and therefore blood pressure should be regularly monitored in patients on this medication. The confusion and dizziness it can cause may increase the risk of falls, which is a significant concern in the elderly population.

Amyloid-Targeting Antibodies

- Drugs: Aducanumab (Aduhelm), Lecanemab (Leqembi), Donanemab (Kisunla)
- Common Side Effects: These newer therapies target amyloid plaques in the brain and can lead to amyloid-related imaging abnormalities.
- Serious Concerns: ARIA can be asymptomatic or cause symptoms such as headache, dizziness, nausea, and, in severe cases, confusion and seizure. Regular MRI monitoring is essential to detect these abnormalities early.

2. Drug-Drug Interactions:

- Alzheimer's patients often take multiple medications for various comorbid conditions, increasing the risk of drug-drug interactions. For example, cholinesterase inhibitors can interact with anticholinergic drugs, reducing their effectiveness and potentially worsening cognitive symptoms. NMDA receptor antagonists like memantine can interact with other medications that affect the central nervous system, leading to enhanced sedative effects or increased confusion.

3. Long-Term Safety Concerns:

- Long-term use of Alzheimer's medications raises concerns about chronic side effects and the potential for cumulative toxicity. For instance, long-term use of cholinesterase inhibitors may lead to sustained gastrointestinal distress or cardiovascular issues. Similarly, the long-term effects of monoclonal antibodies targeting amyloid plaques are not fully understood, and ongoing monitoring for ARIA is necessary even after extended periods of use.

Standard of Care Treatment Options

1. Pharmacological Treatments:

Cholinesterase Inhibitors

- **Purpose:** Typically prescribed in the early to moderate stages to help manage symptoms related to memory, thinking, and language.
- **Clinical Use:** Donepezil is approved for use in all stages, while rivastigmine and galantamine are generally prescribed for mild to moderate stages. These medications can provide temporary improvement in cognitive function or slow the rate of decline.

NMDA Receptor Antagonists

- **Purpose:** Memantine is used to treat moderate to severe Alzheimer's disease. It works by protecting neurons from excessive glutamate activity, which can cause neuronal damage.
- **Clinical Use:** Memantine is often prescribed alone or in combination with a cholinesterase inhibitor for patients with more advanced Alzheimer's disease. It can help improve symptoms related to memory, attention, reason, and the ability to perform simple tasks.

Combination Therapies

- **Example:** Namzaric, a combination of memantine and donepezil, is used to treat moderate to severe Alzheimer's disease.

Monoclonal Antibodies:

- **Purpose:** Designed to target and reduce amyloid plaques in the brain. These plaques are closely associated with Alzheimer's disease, and their reduction is believed to slow disease progression.
- **Clinical Use:** Indicated for early stages of Alzheimer's disease, particularly in patients confirmed to have amyloid pathology through diagnostic imaging or cerebrospinal fluid analysis.

2. Non-Pharmacological Interventions:

Cognitive Therapy

- Purpose: Cognitive therapy involves activities and exercises designed to maintain cognitive function and delay decline. Techniques such as memory training, problem-solving tasks, and social engagement are used to help patients maintain mental function.

Behavioral Interventions

- Purpose: These interventions focus on managing the behavioral symptoms of Alzheimer's disease, such as agitation, aggression, depression, and sleep disturbances.

Lifestyle Modifications

- Purpose: Diet, exercise, and social activity have been shown to influence cognitive health. A healthy diet, regular physical activity, and maintaining social connections can help slow cognitive decline and improve quality of life.

3. Caregiver Support and Education:

- Purpose: Caregivers play a crucial role in managing Alzheimer's disease, often providing both medical and emotional support to patients. Caregiver education focuses on helping them understand the disease, manage symptoms, and provide effective care.

INGENŪ CRO

Strategies to Improve Clinical Trial Protocols for FDA Approval

Improving clinical trial protocols for Alzheimer's Disease is pivotal to advancing our understanding and treatment of the disease. The goal is not only to discover new therapeutic strategies but also to ensure these interventions meet the high safety and efficacy standards required.

1. Cognitive Function Improvement:

- Engage with the FDA early in the drug development process through programs like the Pre-IND meeting.
- Use adaptive trial designs that allow for modifications in the trial based on interim results. This can include adjusting dosing, sample size, or even endpoints based on real-time data.

2. Functional Abilities:

- Digital tools can provide continuous and real-world data, enhancing the accuracy and relevance of the ADCS-ADL endpoint.
- Conduct functional assessment evaluations in parallel with other cognitive assessments, rather than sequentially, saving time by streamlining the data collection process for multiple endpoints.

3. Global Clinical Status:

- Apply for FDA programs such as Breakthrough Therapy Designation or Fast Track Designation if preliminary data suggests the drug offers substantial improvement over existing therapies.
- Utilize real-world evidence from existing treatments or ongoing registries to support the clinical trial data.

4. Biomarker Evidence:

- Leverage biomarkers like amyloid plaque reduction as surrogate endpoints under the FDA's Accelerated Approval Program.
- Ensure early and robust validation of biomarkers in the early stages of drug development. Validated biomarkers can be compelling for accelerated approval, reducing the time to market.

5. Safety and Tolerability:

- Implement integrated safety assessments across all study phases, using data monitoring committees to evaluate safety data in real-time.
- Use safety data from other similar or related drug trials to support the safety profile of the new drug.

6. Patient & Caregiver Reported Outcomes:

- Design trials that integrate patient-reported outcomes (PROs) and caregiver assessments from the outset.
- Utilize digital health platforms to collect and analyze PROs in real-time, enhancing data quality and reducing delays associated with traditional paper-based methods.

Notable Key Opinion Leaders in Alzheimer's Disease Research

Name	Specialty	Designation	Location	Brief Bio
Colin L Masters (MBBS, MD, FRCPA, FAA, FRS)	Neurology	Professor, University of Melbourne	Australia	Professor Colin L. Masters is a leading figure in Alzheimer's disease research. He is a Professor of Dementia Research at The Florey, University of Melbourne and a consultant at the Royal Melbourne Hospital. With a collaborator, he discovered the proteolytic neuronal origin of the Aβ amyloid protein, which causes Alzheimer's disease. He has received numerous accolades, including the Grand Cross of the Order of Merit of the Federal Republic of Germany and the Lifetime Achievement Award from the Alzheimer's Association.
Ralph N Martins (PhD, FAHMS)	Neurology	Director, Edith Cowan University	Australia	Professor Ralph N. Martins is a leading expert in Alzheimer's disease research and the Foundation Chair in Ageing and Alzheimer's Disease at Edith Cowan University. He has made significant contributions to understanding the role of β-amyloid in Alzheimer's pathology and the development of biomarkers for early detection. His work has been recognized globally, earning him awards such as the Officer of the Order of Australia and the Western Australian Scientist of the Year.
Christopher C Rowe (MBBS, MD, FRACP)	Neurology; Nuclear Medicine	Director, Austin Health	Australia	Professor Christopher C. Rowe is a specialist in nuclear medicine and molecular imaging, with a particular focus on Alzheimer's disease. He is the Director of Molecular Imaging Research at Austin Health, Melbourne, Professorial Fellow University of Melbourne, a NHMRC Practitioner Fellow and is the inaugural Director of the Australian Dementia Network. His pioneering work in PET imaging has advanced the diagnosis and understanding of Alzheimer's disease. He has received numerous awards, including the AMRAD Prize and the Australian Radiologist of the Year.
David Ames (MBBS, MD, FRANZCP, FRCPSYCH)	Psychiatry	Professor, University of Melbourne	Australia	Professor David Ames is a leading psychiatrist specializing in old age psychiatry, particularly dementia and Alzheimer's disease. He is a Professor at the University of Melbourne and has been instrumental in developing clinical and research programs for dementia care. His research includes clinical trials for Alzheimer's treatment and the psychosocial aspects of dementia care. He has been awarded the Officer of the Order of Australia for his contributions to psychiatry and dementia care.
Ashley I Bush MBBS, PhD, FRACP)	Neurology; Psychology	Professor, University of Melbourne	Australia	Professor Ashley I. Bush is a renowned neuroscientist and the Director of the Oxidation Biology Unit at the Florey Institute of Neuroscience and Mental Health. His research focuses on the role of metal biology and oxidative stress in neurodegenerative diseases, particularly Alzheimer's disease. His contributions have led to groundbreaking insights into the mechanisms of Alzheimer's disease and the development of new therapeutic approaches. He has been honored with numerous awards, including the Potamkin Prize for Alzheimer's Disease Research.

References

- Humpel, C. (2011). Identifying and validating biomarkers for Alzheimer's disease. *Trends in Biotechnology*, *29*(1), 26-32. https://doi.org/10.1016/j.tibtech.2010.09.007
- Johnson, S., & Smith, L. (2024). The role of sex and sleep disruption in Alzheimer's disease. *Journal of Neuroscience*, *44*(3), 299-308. https://doi.org/10.1523/JNEUROSCI.0874-21.2024
- Khemka, V. K., Ganguly, G., Ghosh, M., Roy, D., Banerjee, A., & Chakrabarti, S. (2023). The role of diet and exercise in aging and Alzheimer's disease. *Frontiers in Aging Neuroscience*, *15*, 105. https://doi.org/10.3389/fnagi.2023.00105
- Khemka, V. K., Ganguly, G., Ghosh, M., Roy, D., Banerjee, A., & Chakrabarti, S. (2023). Socioeconomic factors and Alzheimer's disease risk. *International Journal of Geriatric Psychiatry*, *38*(1), 14-23. https://doi.org/10.1002/gps.5865
- Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., ... & Hyman, B. T. (2012). Correlation of Alzheimer disease neuropathologic changes with cognitive status: A review of the literature. *Journal of Neuropathology & Experimental Neurology*, *71*(5), 362-381. https://doi.org/10.1097/NEN.0b013e31825018f7
- Takizawa, C., Thompson, P. L., van Walsem, A., Faure, C., & Maier, W. C. (2014). Epidemiological and economic burden of Alzheimer's disease: A systematic literature review of data across Europe and the United States. *Journal of Alzheimer's Disease*, *40*(2), 367-379. https://doi.org/10.3233/JAD-131850
- Trejo-Lopez, J. A., Yachnis, A. T., & Prokop, S. (2021). Neuropathology of Alzheimer's disease. *Neurotherapeutics*, *18*(1), 26-36. https://doi.org/10.1007/s13311-020-00941-0

iNGENū CRO

The Australian CRO championing innovative biotech firms for global success.
Delivering high-quality, FDA-compliant clinical research.

If you would like further information on how iNGENū CRO can assist you to conduct your clinical trial, please contact Dr Sud Agarwal or Adam Moodie:

Dr Sud Agarwal
Chief Executive Officer
BSc (Hons), MB ChB FANZCA DDU
dr.sudhanshu@ingenucro.com

Adam Moodie
Director, Scientific Engagement
BSc
adam.moodie@ingenucro.com

Unit 22, 456 St Kilda Road, Melbourne, 3004

www.ingenuCRO.com